Actively Recruiting
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Led by Abramson Cancer Center at Penn Medicine · Updated on 2025-12-04
20
Participants Needed
1
Research Sites
211 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The study is a single-arm phase I trial to evaluate the safety, feasibility, and preliminary efficacy of the addition of pembrolizumab and image-guided resection to surgical therapy and chemotherapy for malignant pleural mesothelioma (MPM).
CONDITIONS
Official Title
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to provide written informed consent
- 18 years of age or older at the time of consent
- Have measurable disease according to RECIST 1.1 criteria
- Willing to provide newly obtained or archived tumor tissue sample
- Performance status of 0 or 1 on the ECOG scale
- Adequate organ function confirmed by labs within 10 days before treatment
- Female of childbearing potential with negative pregnancy test within 72 hours before first dose
- Female of childbearing potential willing to use contraception through 120 days after last dose
- Male of childbearing potential willing to use contraception through 120 days after last dose
You will not qualify if you...
- Participation in another investigational study or use of investigational therapy/device within 4 weeks before treatment
- Diagnosis of immunodeficiency or use of immunosuppressive therapy within 7 days before treatment
- Chronic systemic steroid use exceeding 10 mg prednisone daily within 7 days before treatment
- Known active tuberculosis infection
- Allergy to indocyanine green (ICG), pembrolizumab, or their components
- Prior monoclonal antibody cancer therapy within 4 weeks or unresolved related adverse events
- Prior chemotherapy, targeted therapy, or radiation within 2 weeks or unresolved related adverse events
- Known additional progressing malignancy requiring treatment, except certain skin cancers or in situ cervical cancer
- Known metastatic or unresectable disease
- Active autoimmune disease requiring recent systemic treatment
- History or current pneumonitis requiring steroids
- Evidence of interstitial lung disease
- Active infection requiring systemic therapy
- Conditions or therapies that could interfere with trial participation or results
- Psychiatric or substance abuse disorders interfering with trial cooperation
- Pregnancy or breastfeeding or planning conception during study and 120 days after
- Prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
- Known HIV infection
- Active Hepatitis B or C infection
- Receipt of live vaccine within 30 days before starting study therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Actively Recruiting
Research Team
C
Corey Langer, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here